Label: ORALTAG- iohexol for solution

  • NDC Code(s): 54702-501-21, 54702-501-51, 54702-501-52, 54702-501-62, view more
    54702-501-98, 54702-501-99
  • Packager: Interpharma Praha, a.s.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated November 6, 2019

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use ORALTAG safely and effectively. See full prescribing information for ORALTAG.



    ORALTAG™ (iohexol) for oral solution

    Initial U.S. Approval: 1985

    INDICATIONS AND USAGE

    Oraltag is a radiographic contrast agent indicated for use in opacification of the gastrointestinal tract during computed tomography (CT) of the abdomen and pelvis ( 1)

    Limitations of Use

    Not indicated for diagnostic examination of the gastrointestinal tract ( 1)

    DOSAGE AND ADMINISTRATION

    For oral use only:

    • Adults: 1 to 2 bottles (4.5 g to 9 g iodine (I)) ( 2)
    • Pediatric patients 3 to 18 years of age: less than 1 bottle to 2 bottles (less than 4.5 gI up to 9 gI) ( 2)
    • Pediatric patients less than 3 years of age: up to 1 bottle (4.5 gI) ( 2)

    DOSAGE FORMS AND STRENGTHS

    For oral solution: Each single use bottle contains 9.7 g iohexol (equivalent to 4.5 g carbon bound iodine) (3)

    CONTRAINDICATIONS

    Hypersensitivity to iodinated contrast agents, including iohexol (4)

    WARNINGS AND PRECAUTIONS

    • Hypersensitivity reactions: life-threatening or fatal reactions can occur. Resuscitation equipment and personnel should be available ( 5.2)
    • Thyroid function test alterations: Oraltag may alter tests which depend on iodine estimation. Perform such tests prior to Oraltag administration ( 5.3)

    ADVERSE REACTIONS

    The most common adverse reactions (incidence < 2%) are nausea, vomiting, and diarrhea ( 6)


    To report SUSPECTED ADVERSE REACTIONS, contact Interpharma Praha at 1-877-886-7040 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 4/2015

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Oraltag is indicated for use in computed tomography of the abdomen and pelvis to opacify bowel loops and delineate between normal loops and adjacent organs or areas of suspected pathology.

    Limitations of Use

    Oraltag is not indicated for diagnostic examination of the gastrointestinal tract.

  • 2 DOSAGE AND ADMINISTRATION

    2.1  Recommended Dosing

    For oral use only[see Warnings and Precautions (5.1)]

    Refer to Table 1 for dosing information.

    Table 1 Dosing Guidelines for Oraltag

    *
    Total volume of Oraltag administered will vary depending on the size of the patient

    Patient Age

    Recommended Dose *

    Volume of Prepared
    Solution to Administer
    (at a concentration of
    9 mgI per mL)

    Maximum
    Total Iodine
    Dose

    Adults

    Administer 4.5 g to 9 g of iodine (1 to 2 bottles of prepared solution), orally

    500 mL to 1000 mL

    9 grams

    3 to 18 years of age

    Administer up to 9 g of iodine (from less than 1 bottle up to 2 bottles of prepared solution), orally

    280 mL to 750 mL,
    depending on size of patient

    9 grams

    Less than 3 years of age

    Administer up to 4.5 g of iodine (portion of 1 bottle of prepared solution), orally

    120 mL to 300 mL,
    depending on size of patient

    4.5 grams

    The variables of patient age, weight, or medical condition, may require adjustment of the concentration and/or volume of solution to be prepared for administration. If it is anticipated that the patient will have difficulty in consuming the required volume, a higher concentration of solution (up to 21 mgI per mL) can be prepared and a smaller volume administered (see Table 2).

    Table 2 Preparation of Higher Concentrations of Oraltag at Lower Volumes

    *
    Examples include infant formula, milk, juice, carbonated beverage or a sports drink

    For Final Concentration
    (mgI/mL)

    Add Water or a Beverage * to the Indicated Mark on the Bottle

    (mL)

    9

    500

    12

    375

    15

    300

    18

    250

    21

    214

    2.2  Preparation and Administration Instructions

    • Reconstitute Oraltag, supplied as a powder in a single use bottle, with water or other beverages just before its use
    • Do not mix other pharmaceuticals with Oraltag
    • Use the 5 fill lines premolded and labeled on the bottle to determine the volume for the 5 target concentrations (9, 12, 15, 18, and 21 mgI/mL)
    • Administer Oraltag 20 to 60 minutes before image acquisition
    • Protect prepared solution from strong daylight and direct exposure to sunlight
    • Discard any unused portions
  • 3 DOSAGE FORMS AND STRENGTHS

    For oral solution: Oraltag is provided as a white to off-white powder of 9.7 g iohexol, (equivalent to 4.5 g of carbon bound iodine) in a single-use bottle.

  • 4 CONTRAINDICATIONS

    Oraltag is contraindicated in patients with a known hypersensitivity to iodinated contrast agents, including iohexol [see Warnings and Precautions (5.2)] .

  • 5 WARNINGS AND PRECAUTIONS

    5.1  Risks Associated with Inadvertent Parenteral Administration

    Oraltag is not a sterile product and is not suitable for a parenteral route of administration. Serious adverse reactions such as sepsis can occur if administered parenterally. Do not administer Oraltag parenterally.

    5.2  Hypersensitivity Reactions

    Administration of Oraltag can cause life-threatening hypersensitivity reactions including anaphylaxis [see Contraindications (4)] . Patients at increased risk include those with a previous reaction to an iodinated contrast agent and allergic disorders (i.e., bronchial asthma, allergic rhinitis, and food allergies). Emergency resuscitation equipment and trained personnel should be available.

    5.3  Alteration of Thyroid Function Tests

    Iodinated contrast agents may alter the results of thyroid function tests which depend on iodine estimation, e.g., radioactive iodine uptake test. Therefore, such testing, if indicated, should be performed prior to the administration of this preparation.

  • 6 ADVERSE REACTIONS

    The following adverse reactions are described in greater detail in other sections:

    6.1  Clinical Trials Experience

    In studies involving 44 adult and 69 pediatric patients who received oral and intravenous iohexol for CT examinations of the abdomen, two reports of vomiting (2%) were noted.

    6.2  Postmarketing Experience

    Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    The following adverse reactions have been reported following oral administration of the dilute, hypotonic solutions of iohexol (9 mgI/mL to 21 mgI/mL):

    • Gastrointestinal: nausea, diarrhea
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no human data on risks associated with the use of Oraltag during pregnancy. The background risk in the U.S. general population of major birth defects is 2% to 4% and risk of miscarriage is 15% to 20% of clinically recognized pregnancies. In animal reproduction studies, no evidence of fetal harm was observed with intravenous administration of iohexol to rats and rabbits at doses up to 100 times the maximum recommended human intravenous dose.

    8.2 Lactation

    Risk Summary

    Iohexol administered intravenously is present in human milk at concentrations approximately 0.5% of the maternal dose; however, it is not known to what extent iohexol administered orally is present in human milk. Iodinated contrast is poorly excreted into human milk and is poorly absorbed by the gastrointestinal tract of a breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Oraltag and any potential adverse effects on the breastfed infant from Oraltag.

    Clinical Considerations

    Interruption of breastfeeding after exposure to iodinated contrast media is not necessary because the potential exposure of the breastfed infant to iodine is small. However, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 10 hours (approximately 5 half-lives) after Oraltag administration in order to minimize potential drug exposure to a breastfed infant.

    8.4 Pediatric Use

    The safety and effectiveness of oral iohexol have been established in pediatric patients.

    8.5 Geriatric Use

    In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

  • 11 DESCRIPTION

    Oraltag (iohexol) is a radiographic contrast agent for oral solution. Oraltag is provided as a nonsterile white to off-white powder with 9.7 g iohexol (equivalent to 4.5 g of carbon bound iodine) in a 20-ounce beverage bottle. Each bottle is individually sealed in a foil laminated pouch. Oraltag consists of 100 percent iohexol and contains no excipients.

    Iohexol is designated chemically as N,N´-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide. It is a nonionic, water-soluble iodinated contrast medium with a molecular weight of 821.14 (carbon bound iodine content 46.36%). In aqueous solution each triiodinated molecule remains undissociated.

    The chemical structure is:

    Chemical Structure

    Oraltag, when prepared at a concentration of 9 mgI/mL in water, has an osmolality of 30 mOsmol/kg water. The calculated osmolality of 21 mgI/mL in water is 55 mOsmol/kg water. The prepared solutions are hypotonic.

  • 12 CLINICAL PHARMACOLOGY

    12.1  Mechanism of Action

    Iohexol enhances imaging due to its high iodine content attenuating the beam of X-rays during CT examinations. Different tissues within the body attenuate X-rays to different degrees, and oral administration of iohexol allows for enhanced visualization due to the iodine present in bowel loops.

    12.3 Pharmacokinetics

    Orally administered iohexol is very poorly absorbed from the normal gastrointestinal tract. Only 0.1 to 0.5% of the oral dose is excreted by the kidneys. This amount may increase in the presence of bowel perforation, bowel obstruction, or severe inflammatory bowel disease.

    Iohexol displays a low affinity for serum or plasma proteins and is poorly bound to serum albumin. No significant metabolism, deiodination or biotransformation occurs.

  • 13 NONCLINICAL TOXICOLOGY

    13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term animal studies have been performed to evaluate carcinogenic potential or mutagenesis.

    In animal reproduction studies, no evidence of impaired fertility was observed with intravenous administration of iohexol to rats and rabbits at doses up to 100 times the maximum recommended human intravenous dose.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    Oraltag is supplied as a nonsterile white to off-white powder for oral solution in a single-use 20-ounce polyethylene terephthalate beverage bottle closed with a lined polypropylene cap. Each bottle is packaged in a sealed foil pouch.

    Twelve (12) bottles per pack (NDC 54702-501-52).

    Twenty-five (25) bottles per pack (NDC 54702-501-62).

    Storage

    Store at controlled room temperature, 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

    Protect prepared solutions of Oraltag from strong daylight and direct exposure to sunlight.

    Do not use if tamper-evident foil pouch has been opened.

  • 17 PATIENT COUNSELING INFORMATION

    Hypersensitivity Reactions

    Advise patients about the risk of hypersensitivity reactions to Oraltag and the need to notify their healthcare provider if signs or symptoms of hypersensitivity reaction occur [see Warnings and Precautions (5.2)] .

  • SPL UNCLASSIFIED SECTION

    Manufactured for Interpharma Praha, a.s., Prague, Czech Republic by Ultra Seal Corporation, New Paltz, New York.

  • PRINCIPAL DISPLAY PANEL - 9.7 g Bottle Label

    NDC 54702-501-21

    Oraltag™

    (iohexol) for oral solution

    9.7 g of iohexol powder
    (equivalent to 4.5 g of carbon bound iodine)


    Single Use Bottle - Discard Unused Portion

    Prepared solution is 9-21 mgI/mL

    For Oral Use Only
    Nonsterile

    For indications and dosage, see prescribing information.

    Store at 20-25˚C (68-77˚F); excursions permitted to 15-30˚C (59-86˚F) [see USP]

    Protect prepared solutions of Oraltag from strong daylight and direct exposure to sunlight.

    Rx Only

    Manufactured for Interpharma Praha, a.s.
    Prague, Czech Republic
    by Ultra Seal Corporation
    New Paltz, New York


    PRINCIPAL DISPLAY PANEL - Bottle Label

  • PRINCIPAL DISPLAY PANEL - Foil Pouch Label

    NDC 54702-501-51

    Oraltag™

    (iohexol) for oral solution

    Contains a single-use bottle with 9.7 g of iohexol powder
    (equivalent to 4.5 g of carbon bound iodine)

    For Oral Use Only
    Nonsterile

    Store at 20-25˚C (68-77˚F); excursions permitted to 15-30˚C (59-86˚F) [see USP]

    Rx Only

    Manufactured for Interpharma Praha, a.s.
    Prague, Czech Republic
    by Ultra Seal Corporation
    New Paltz, New York

    Instructions for Use:

    1. Add water or beverage up to the fill line on the bottle as prescribed for the patient. Prepare one or two bottles as directed.

    2. Replace cap and shake until all the powder has dissolved.

    3. The dose is ready to be consumed by the patient.

    4. Discard any unused portion.

    PRINCIPAL DISPLAY PANEL - Pouch Label FrontPRINCIPAL DISPLAY PANEL - Pouch Label Back

  • INGREDIENTS AND APPEARANCE
    ORALTAG 
    iohexol for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:54702-501
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    IOHEXOL (UNII: 4419T9MX03) (IOHEXOL - UNII:4419T9MX03) IODINE4.5 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:54702-501-5212 in 1 CASE07/01/2016
    1NDC:54702-501-511 in 1 POUCH
    1NDC:54702-501-211 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2NDC:54702-501-6225 in 1 CASE07/01/2016
    2NDC:54702-501-511 in 1 POUCH
    2NDC:54702-501-211 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    3NDC:54702-501-9812 in 1 CASE07/01/2016
    3NDC:54702-501-991 in 1 POUCH
    3NDC:54702-501-211 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20538307/01/2016
    Labeler - Interpharma Praha, a.s. (644354706)
    Establishment
    NameAddressID/FEIBusiness Operations
    Ultra Seal Corporation085752004pack(54702-501) , label(54702-501)
    Establishment
    NameAddressID/FEIBusiness Operations
    Interpharma Praha, a.s.644354706api manufacture(54702-501) , analysis(54702-501) , manufacture(54702-501)